{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:15:19Z","timestamp":1791227719108,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T00:00:00Z","timestamp":1482105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"LG Life Sciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:p>\n                    We aimed to investigate the effects of gemigliptin, a dipeptidyl peptidase\u20104 inhibitor, on postprandial lipoprotein levels and endotoxemia in a randomized, double\u2010blind, placebo\u2010controlled, crossover study. Ten people with type 2 diabetes mellitus (\n                    <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                    ), inadequately controlled with oral antidiabetic medications and\/or lifestyle modification, were randomized to gemigliptin or placebo for 4 weeks. At the end of each treatment phase, the study participants underwent a high\u2010fat meal tolerance test and needle aspiration of abdominal subcutaneous adipose tissue. The median (range) fasting and total area under the curve of apolipoprotein\n                    <jats:styled-content style=\"fixed-case\">B48<\/jats:styled-content>\n                    (\n                    <jats:styled-content style=\"fixed-case\">ApoB48<\/jats:styled-content>\n                    ) were significantly lower with gemigliptin than with placebo (2.9 [1.5\u201015.8] \u00b5g\/\n                    <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                    vs 4.2 [1.3\u201023.4] \u00b5g\/\n                    <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                    ;\n                    <jats:italic>P<\/jats:italic>\n                    = .020; 35.3 [14.4\u201087.4] \u00b5g\/\n                    <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                    \u00d7 hour vs 42.2 [17.5\u2010109.0] \u00b5g\/\n                    <jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\n                    \u00d7 hour;\n                    <jats:italic>P<\/jats:italic>\n                    = .020, respectively), whereas apolipoprotein\n                    <jats:styled-content style=\"fixed-case\">B100<\/jats:styled-content>\n                    showed no significant difference. Serum endotoxin levels were undetectable in 70% of the samples, so we were not able to evaluate the effect of gemigliptin on endotoxemia. The gene expression of inflammatory cytokines in subcutaneous adipose tissue was not affected by gemigliptin. Gemigliptin reduced\n                    <jats:styled-content style=\"fixed-case\">ApoB48<\/jats:styled-content>\n                    levels after a high\u2010fat meal in participants with\n                    <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>\n                    . Whether systemic endotoxin levels can be reduced by gemigliptin requires further investigation.\n                  <\/jats:p>","DOI":"10.1111\/dom.12831","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T01:02:55Z","timestamp":1479690175000},"page":"457-462","source":"Crossref","is-referenced-by-count":9,"title":["Effects of gemigliptin, a dipeptidyl peptidase\u20104 inhibitor, on lipid metabolism and endotoxemia after a high\u2010fat meal in patients with type 2 diabetes"],"prefix":"10.1111","volume":"19","author":[{"given":"Chang Ho","family":"Ahn","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Seoul National University Hospital  Seoul Korea"},{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ky","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University Hospital  Seoul Korea"},{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hee","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University Hospital  Seoul Korea"},{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Jung","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul Korea"},{"name":"Department of Internal Medicine Seoul National University Bundang Hospital  Seongnam Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Min","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University Hospital  Seoul Korea"},{"name":"Department of Internal Medicine Seoul National University College of Medicine  Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,12,19]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e3282ffaf82"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1593"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/db06-1491"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2197"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00303.2004"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.165886"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0376-x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0340-2"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01362.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-8"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2016.40.5.339"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.8.2.268"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1654"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12359"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M800156-JLR200"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2015.06.020"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2518"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12831","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:44Z","timestamp":1761871064000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,19]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/dom.12831"],"URL":"https:\/\/doi.org\/10.1111\/dom.12831","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,19]]}}}